Catalent Launches IPO; Its CEO Talks Strategy

Yesterday, Catalent, Inc.,  a specialist in advanced delivery technologies and development solutions for drugs, biologics and consumer health products,  launched its initial public offering of 42,500,000 shares of its common stock at $20.50 per share. The shares began trading on the New York Stock Exchange yesterday under the ticker symbol “CTLT,” and the offering is expected to close on August 5, 2014, subject to customary closing conditions. For an interview with the company’s CEO, on The Street, click here. 

Catalent has granted the underwriters a 30-day option to purchase up to an additional 6,375,000 at the initial public offering price. Catalent expects to receive net proceeds of approximately $822.7 million after deducting underwriting discounts and estimated offering expenses, and intends to use the proceeds to reduce debt.

Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman, Sachs & Co., Jefferies and Deutsche Bank Securities are acting as joint bookrunning managers for the offering. Blackstone Capital Markets, Piper Jaffray, Raymond James, Wells Fargo Securities, William Blair and Evercore are acting as co-managers for the offering. A registration statement relating to shares of the common stock of Catalent has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (“SEC”). The registration statement is available on the SEC’s website at www.sec.gov under the registrant’s name.  The offering of the shares of common stock will be made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department., 180 Varick Street, 2nd Floor, New York, NY 10014; or from J.P. Morgan, Attention: Prospectus Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717 or via telephone: +1 (866) 803-9204.